Wait...
Search Global Export Import Trade Data
Recent Searches: No Recent Searches

FDI in Pharma Likely To Need Govt Approval.


Date: 22-09-2011
Subject: FDI in Pharma Likely To Need Govt Approval
With large Indian pharma companies like Ranbaxy Laboratories being taken over by global players in recent years, the government is likely to put foreign direct investment in bro­wnfield pharma companies under approval route.

Presently, 100 per cent foreign direct investment is allowed under automatic route both in greenfield investments and in existing Indian pharma companies.

Putting FDI in existing Indian pharma companies under approval route wou­ld not amount to rollback of the foreign investment policy, as “FDI in the sector is not being restricted but only a procedural filter is proposed,” a government official said on Wednesday.

Commerce and industry minister Anand Sharma has already written a letter to prime minister Manmohan Singh in this regard and a meeting is scheduled next month to deal with the pressing issue.

In recent years, there has been several takeovers of Indian pharmaceutical companies by multinational players. A record $8.99 billion FDI has come into drugs and pharmaceuticals in past one decade. Nearly half of it, $4.73 billion, has been through mergers and acquisitions in form of brownfield investments.

Apart from Ranbaxy’s takeover by Japan’s Daiichi Sankyo, other major acquisitions are Matrix Lab by Mylan of the US, Dabur Pharma by Fresenius Kabi of Singapore, Shanta Biotech by Sanofi Aventis of France, Orchid chemicals by Hospira of and Piramal Healthcare by Abbott Lab of the US.

Department of industrial policy and promotion (DIPP) has proposed change in FDI norms following red flag raised by health ministry on such takeovers that this is likely to affect government’s efforts at making available lower priced versions of generic drugs. Health ministry also feared that such takeovers are likely to create an oligopolistic market with large companies working as cartel.

India's pharmaceutical industry is now the third largest in the world in terms of volume. The total turnover of India's pharmaceutical industry was $21.04 billion, according to latest available estimates. The domestic market was worth $12.26 billion.

In the domestic market, Cipla retained its leadership position with 5.27 per cent share. The highest growth was for Mankind Pharma (37.2 per cent). The Indian pharmaceuticals market is expected to reach $55 billion in 2020 from $12.6 billion now.

President of Indian Pharmaceuticals Association (IPA) C Gopalkrishna Murty told Financial Chronicle there are at least 200 Indian pharma companies that could be targeted for takeover by foreign companies. But, at the moment he is not aware of any Indian pharma company being in the radar for foreign takeover.

He said there are apprehensions that there could be more takeovers by foreign pharma companies and hence government could be considering putting FDI in brownfield companies through the approval route to keep a tab on takeovers.

There are at least 800 Indian pharma companies registered as members with Indian Drug Manufacturers Association. Its rival, Organisation of Pharmaceutical Producers of India (OPPAI) has mostly multinational drug companies operating in India as its members.

DIPP has convened an inter-ministerial meeting in February 2011 to discuss the issue. DIPP is not averse to continuing the policy of allowing 100 per cent FDI through the automatic route in setting up new pharmaceutical units to make India a major destination for FDI in quality drug research, development and manufacturing of both bulk drugs, intermediates and formulations.

Indian generic pharma industry has in recent years posed a major challenge to multinationals through production and export of low cost high quality medicines as well as patent challenges and hence there are fears of more takeovers.

Source : mydigitalfc.com


Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+


What is New?

Date: 06-06-2025
Notification No. 13/2025-Customs (ADD)
Seeks to impose Anti Dumping Duty on imports of ‘Insoluble Sulphur’ originating in or exported from China PR and Japan.

Date: 30-05-2025
Notification No. 31/2025-Customs
Seeks to i. extend the specified condition of exemption to imports of Yellow Peas (HS 0713 10 10) to bill of lading issued on or before 31.03.2026; ii. to reduce the basic custom duty on crude soya bean oil (HS Code 15071000), crude sunflower oil (HS Code 15121110), and crude palm oil (HS Code 15111000) from 20% to 10%

Date: 30-05-2025
Notification No. 38/2025-CUSTOMS (N.T.)
Fixation of Tariff Value of Edible Oils, Brass Scrap, Areca Nut, Gold and Silver

Date: 26-05-2025
NOTIFICATION No. 37/2025-Customs (N.T.)
Notification of ICD Jalna, Maharashtra u/s. 7(1)(aa) of Customs Act, 1962" and it was issued under Section 7(1)(aa) of Customs Act, 1962

Date: 23-05-2025
Notification No. 30/2025-Customs
Seeks to amend notification No. 55/2022-Customs dated 31.10.2022 to remove the condition required for availing exemption on Bangalore Rose Onion.

Date: 23-05-2025
NOTIFICATION No. 36/2025 - Customs (N.T.)
Amendment in the Notification No. 63-1994-Customs (N.T) dated 21.11.1994 in respect of Land Customs Station, Raxaul

Date: 15-05-2025
Notification No. 34/2025-CUSTOMS (N.T.)
Fixation of Tariff Value of Edible Oils, Brass Scrap, Areca Nut, Gold and Silver

Date: 09-05-2025
Notification No. 29/2025-Customs
Seeks to exempt works of art and antiques from Basic Customs Duty

Date: 30-04-2025
Notification No. 02/2025-Customs (CVD)
Seeks to amend Notification No. 05/2024-Customs (CVD) dated the 11th September, 2024 so as to align with changes made vide Finance Act, 2025

Date: 30-04-2025
Notification No. 26/2025-Customs
Seeks to rescind Notification No. 04/2025-Customs dated the 1st February, 2025



Exim Guru Copyright © 1999-2025 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.

EximGuru.com

C/o InfodriveIndia Pvt Ltd
F-19, Pocket F, Okhla Phase-I
Okhla Industrial Area
New Delhi - 110020, India
Phone : 011 - 40703001